Methods of treating cancer patients with farnesyltransferase inhibitors
AssigneeKura Oncology, Inc.
InventorsAntonio GUALBERTO, Catherine Rose SCHOLZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
Claims30
A method of treating a H-Ras mutant HNSCC in a subject, consisting of administering a therapeutically effective amount of tipifarnib to said subject, wherein said HNSCC is at an advanced stage, metastatic, relapsed or refractory.
A method of treating a H-Ras mutant relapsed or refractory head and neck squamous cell carcinoma (HNSCC) in a subject, comprising administering a therapeutically effective amount of tipifarnib to said subject.
Dependencies are inferred from the claim text.